Literature DB >> 32167569

Trends in Parity and Breast Cancer Incidence in US Women Younger Than 40 Years From 1935 to 2015.

Sarah M Lima1, Rebecca D Kehm1, Katrina Swett2, Lou Gonsalves2, Mary Beth Terry1,3.   

Abstract

Importance: During the past several decades, breast cancer incidence has been increasing for women younger than 40 years. The increase matches the decrease in parity, an established breast cancer risk factor, but secular trends in incidence have not been examined prior to the 1970s. Objective: To examine whether secular trends in parity explain the increase in breast cancer incidence among US women aged 25 to 39 years from 1935 to 2015. Design, Setting, and Participants: This population-based cohort study used population-based aggregate-level data from the Connecticut Tumor Registry (CTR) to examine breast cancer incidence and age-standardized rates among women aged 25 to 39 years from 1935 to 2015. National mean live births were calculated using birth data from the National Vital Statistics System (NVSS) from 1930 to 2015 (allowing for 5-year lag). Linear regression was used to compare a baseline model of year estimating age-adjusted breast cancer incidence rate with a model that adjusted for parity constructs. Main Outcomes and Measures: Breast cancer incidence rates among women aged 25 to 39 years from 1935 to 2015.
Results: Among women in Connecticut aged 25 to 39 years from 1935 to 2015, incidence of breast cancer for women aged 25 to 39 years increased 0.65% (95% CI, 0.53%-0.77%) per year, from 16.3 breast cancer diagnoses per 100 000 women in 1935 to 38.5 breast cancer diagnoses per 100 000 women in 2015. This increase began nearly 4 decades before the secular decrease in parity (mean [SD] parity peaked at 2.26 [0.87] live births per woman in 1966 and in 2010 had decreased to 1.41 [0.71] live births per woman). Age-specific parity trends explained only 0% to 4% of the variability in incidence over time. Conclusion and Relevance: These findings suggest that breast cancer incidence for women aged 25 to 39 years has been significantly increasing since the 1930s and cannot be attributed to changes in parity over time.

Entities:  

Year:  2020        PMID: 32167569     DOI: 10.1001/jamanetworkopen.2020.0929

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


  11 in total

1.  Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional study.

Authors:  Anushri Chitkara; Ines Mesa-Eguiagaray; Sarah H Wild; Peter S Hall; David A Cameron; Andrew H Sims; Jonine D Figueroa
Journal:  Breast Cancer Res Treat       Date:  2022-09-18       Impact factor: 4.624

Review 2.  Is early-onset cancer an emerging global epidemic? Current evidence and future implications.

Authors:  Tomotaka Ugai; Naoko Sasamoto; Hwa-Young Lee; Mariko Ando; Mingyang Song; Rulla M Tamimi; Ichiro Kawachi; Peter T Campbell; Edward L Giovannucci; Elisabete Weiderpass; Timothy R Rebbeck; Shuji Ogino
Journal:  Nat Rev Clin Oncol       Date:  2022-09-06       Impact factor: 65.011

Review 3.  Oncobiology and treatment of breast cancer in young women.

Authors:  Rakesh Kumar; Catarina Abreu; Masakazu Toi; Sunil Saini; Sandra Casimiro; Anshika Arora; Aswathy Mary Paul; Ravi Velaga; Pranela Rameshwar; Allan Lipton; Sudeep Gupta; Luis Costa
Journal:  Cancer Metastasis Rev       Date:  2022-04-30       Impact factor: 9.237

4.  Long-term PM2.5 exposure before diagnosis is associated with worse outcome in breast cancer.

Authors:  Diddier Prada; Andrea A Baccarelli; Mary Beth Terry; Leonora Valdéz; Paula Cabrera; Allan Just; Itai Kloog; Haydee Caro; Claudia García-Cuellar; Yesennia Sánchez-Pérez; Rodrigo Cruz; Jose Diaz-Chávez; Carlo Cortés; Delia Pérez; Abelardo Meneses-García; David Cantú-de-León; Luis A Herrera; Enrique Bargalló
Journal:  Breast Cancer Res Treat       Date:  2021-03-08       Impact factor: 4.624

5.  Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data.

Authors:  Ines Mesa-Eguiagaray; Sarah H Wild; Philip S Rosenberg; Sheila M Bird; David H Brewster; Peter S Hall; David A Cameron; David Morrison; Jonine D Figueroa
Journal:  Br J Cancer       Date:  2020-06-19       Impact factor: 7.640

Review 6.  Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation.

Authors:  Hanne Lefrère; Liesbeth Lenaerts; Virginia F Borges; Pepper Schedin; Patrick Neven; Frédéric Amant
Journal:  Int J Gynecol Cancer       Date:  2021-03       Impact factor: 3.437

7.  Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes.

Authors:  Sonali Jindal; Nathan D Pennock; Duanchen Sun; Wesley Horton; Michelle K Ozaki; Jayasri Narasimhan; Alexandra Q Bartlett; Sheila Weinmann; Paul E Goss; Virginia F Borges; Zheng Xia; Pepper Schedin
Journal:  Nat Commun       Date:  2021-11-03       Impact factor: 14.919

8.  Polycyclic Aromatic Hydrocarbons and Mammary Cancer Risk: Does Obesity Matter too?

Authors:  Lydia Lichtiger; Janelle Rivera; Debashish Sahay; Rachel L Miller
Journal:  J Cancer Immunol (Wilmington)       Date:  2021

9.  Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns.

Authors:  Sarah M Lima; Rebecca D Kehm; Mary Beth Terry
Journal:  EClinicalMedicine       Date:  2021-07-07

10.  Aberrant RET expression affects normal mammary gland post-lactation transition, enhancing cancer potential.

Authors:  Sabrina A Vallone; Martín García Solá; Carolina Schere-Levy; Roberto P Meiss; Gladys N Hermida; Lewis A Chodosh; Edith C Kordon; Nancy E Hynes; Albana Gattelli
Journal:  Dis Model Mech       Date:  2022-03-29       Impact factor: 5.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.